The upgrade follows recent developments at Sentynl Therapeutics, a subsidiary of Zydus Lifesciences, which secured U.S. FDA ...
Amgen Inc. ( AMGN) Q4 2025 Earnings Call February 3, 2026 4:30 PM EST ...
The company's 10-Ks for fiscal year 2025 identify certain factors that could cause the company's actual results to differ ...
Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company.
DelveInsight's Insulin Resistance Market Insights report includes a comprehensive understanding of current treatment practices, insulin resistance emerging drugs, market share of individual therapies, ...
The insulin resistance market is expected to grow steadily over the forecast period (2026-2036). According to DelveInsight's analysis, this growth is driven by the rising global prevalence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results